SCHEMBL4882273

SCHEMBL4882273

CC(C)(C)c1ccc(C(=O)NN=C(C=NO)c2ccc(Oc3ccccc3)cc2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESRRG P62508 2/20 0.46
AGTR1 P30556 1/20 0.45
RAB9A P51151 4/20 0.44
POLB P06746 2/20 0.44
NPC1 O15118 2/20 0.44
CASP3 P42574 1/20 0.44
SENP7 Q9BQF6 1/20 0.44
LMNA P02545 3/20 0.43
MAPK1 P28482 1/20 0.43
MAPT P10636 2/20 0.42
TDP1 Q9NUW8 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
ALDH1A1 P00352 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
FABP1 P07148 1/20 0.41
MAPK14 Q16539 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4882268 1.00 ESRRG (0.46) ESRRGAGTR1RAB9APOLBNPC1
SCHEMBL4884917 0.90 ESRRG (0.56) ESRRGAGTR1RAB9ANPC1CASP3
SCHEMBL4884919 0.90 ESRRG (0.56) ESRRGAGTR1RAB9ANPC1CASP3
SCHEMBL4877413 0.87 MCL1 (0.50) RAB9APOLBNPC1LMNAMAPT
SCHEMBL4877421 0.87 MCL1 (0.50) RAB9APOLBNPC1LMNAMAPT
SCHEMBL5716131 0.85 ESRRG (0.50) ESRRGAGTR1RAB9APOLBNPC1
SCHEMBL5716137 0.85 ESRRG (0.50) ESRRGAGTR1RAB9APOLBNPC1
SCHEMBL4928562 0.82 RAB9A (0.62) RAB9ANPC1LMNAMAPTTDP1
SCHEMBL4882658 0.82 RAB9A (0.62) RAB9ANPC1LMNAMAPTTDP1
SCHEMBL4882668 0.82 RAB9A (0.62) RAB9ANPC1LMNAMAPTTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080227787-A1 Use of New Lipoxygenase Inhibitors BIOLIPOX AB (SE) 2008-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227787-A1 Use of New Lipoxygenase Inhibitors ALOX15, ALOX15B, ALOX12 ESRRG 1722/4885AGTR1 1045/4885RAB9A 3811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.